The BH3-Mimetic Obatoclax Restores the Response to Dexamethasone in Glucocorticoid-Resistant ALL through Induction of Autophagy.

Laura Bonapace(University Children's Hospital Zurich), Jean‐Pierre Bourquin(University Children's Hospital Zurich), Gunnar Cario, Beat Bornhäuser(University Children's Hospital Zurich), Beat Schaefer(University Hospital Zurich), Felix Niggli(University of Zurich), Martin Schrappe(University Hospital Schleswig-Holstein)

Blood

November 16, 2007

10.1182/blood.v110.11.806.806

Cited by 3

Related Papers

Childhood Acute Lymphoblastic Leukemia: Progress Through Collaboration

|Journal of Clinical Oncology|2015|1k

Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood

|The Lancet|1998|964

Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95

|Blood|2008|607

Outcome of treatment in childhood acute lymphoblastic leukaemia with rearrangements of the 11q23 chromosomal region

|The Lancet|2002|401

Down syndrome acute lymphoblastic leukemia, a highly heterogeneous disease in which aberrant expression of CRLF2 is associated with mutated JAK2: a report from the International BFM Study Group

|Blood|2009|347